NativeMed markets direct-pay access to compounded semaglutide and tirzepatide. Its default product cards quote $149 and $183 per month, respectively, but ask for three months of payment upfront. For someone moving from an employer benefit to self-pay, the useful comparison is the amount committed today and what can be recovered if the arrangement changes.
This review examines NativeMed’s public product pages, enrollment terms and refund policy as checked on October 15, 2026. It also considers an FDA warning letter addressed to NativeMed LLC. We did not enroll, submit medical information, order medication or test the service. The assessment has no clinical-quality score or independently verified patient-outcome claim.
Read the payment period beside the price
The semaglutide product page displays $447 paid upfront for a three-month plan; the tirzepatide page displays $549 upfront. Dividing those totals by three produces the advertised monthly equivalents. It does not turn either purchase into a $149 or $183 monthly installment.
Public offers checked October 15; confirm the selected plan before payment
| Treatment | Default three-month offer | Separate monthly offer in product-page copy |
|---|---|---|
| Compounded semaglutide | $447 upfront; $149 monthly equivalent | $159 first month; $179 per month thereafter |
| Compounded tirzepatide | $549 upfront; $183 monthly equivalent | $199 first month; $259 per month thereafter |
Scroll the table sideways to see every column.
The public page also contains the separate monthly-plan figures shown above. Our rendered default view displayed the three-month offer, and selecting Monthly did not expose a different price during our check. Treat the alternate monthly copy as a published offer to confirm, not proof that a particular checkout will charge it. We did not complete checkout or establish the renewal amount for an individual account.
NativeMed advertises the same price across doses, free shipping if prescribed and no hidden fees. Its January 10, 2024 enrollment terms nevertheless describe additional consultation and maintenance-call charges. Obtain a written explanation of which terms apply to the current product offer before relying on the broad no-fee language.
A short refund window does not mean a free cancellation
The refund policy, also dated January 10, 2024, makes subscription and one-time program payments generally nonrefundable. Its stated exception allows a refund request within 24 hours of purchase, before medication has shipped, with an administrative cancellation fee. The policy does not specify the amount of that fee. Both the time limit and shipment condition matter.
Requests go to partners@nativemed.net; the policy gives “Cancellation Request” as the email subject. It says eligible card refunds will be credited within ten business days after NativeMed confirms eligibility. That is a company processing promise, not a tested bank-credit date. Asking to stop a program and obtaining a refund for an already-paid term are separate questions.
The enrollment terms allow termination on prior written notice, but the pages checked do not give a clear recurring-payment cutoff for every current plan. Ask whether a three-month purchase renews, its next charge date, how to disable renewal and whether a cancellation affects future billing only. Keep the confirmation with the original order terms.
Consultation and care arrangements need a written explanation
The enrollment terms call the initial virtual consultation free, then say a $25 fee may apply if someone decides not to proceed on the call. They separately list a $25 cancellation or no-show fee for canceling within two hours of the appointment or missing it. Maintenance calls carry an additional, unspecified charge. These are distinct potential charges; they should not be collapsed into the headline medication price.
NativeMed LLC is the operator named in the terms. The product pages describe an online health questionnaire, review by a licensed provider and fulfillment by a partner pharmacy if prescribed. We did not independently verify the license of an assigned clinician, identify the pharmacy for a particular order or inspect a dispensed product. Request those identities before proceeding.
The product FAQ says NativeMed does not bill insurance; HSA or FSA cards may be accepted where eligible. Acceptance of a payment card does not establish benefit eligibility. The enrollment terms also make patients responsible for outside diagnostic tests or specialist services. Use our employer-benefit versus self-pay guide to separate those costs from any existing coverage.
What the FDA letter establishes
FDA’s June 8, 2026 warning letter, reference 728287, describes a March 2026 website review. The agency objected to NativeMed-branded tirzepatide labeling that suggested NativeMed was the compounder and to a semaglutide claim that implied FDA approval or evaluation. FDA characterized the cited representations as false or misleading. This is an attributed regulatory finding, not our independent product test.
The current product pages use different explanatory language. That observation does not establish FDA closure of the letter or resolution of every concern; our sources do not confirm either. FDA’s general guidance explains that compounded GLP-1 products are not FDA-approved and are not reviewed for safety, effectiveness or quality before marketing. Branded-drug trial results cannot establish the performance of an individual compounded preparation.
Delivery promises are narrower than a care guarantee
The product FAQ estimates shipment within one to three business days after prescription approval and pharmacy processing. Elsewhere the page refers to overnight delivery. Pharmacy preparation and carrier transit are different stages, and neither statement measures time from checkout to clinical approval. We did not test shipping, temperature control or support response time.
Our assessment is that the published upfront totals are useful, but the older enrollment language, unspecified cancellation fee and FDA history leave material questions. Compare Effecty’s billing and cancellation terms, then ask NativeMed for the exact renewal schedule, applicable fees, clinical group and dispensing pharmacy. A lower monthly equivalent is only useful when the commitment and refund exposure fit your circumstances.
Sources and review limits
Public sources checked October 15, 2026. Provider statements are commercial claims unless attributed to another source. No patient test, individual eligibility decision or clinical-quality rating was performed.
Continue your research
Educational provider research. A licensed clinician must determine whether a treatment is appropriate; this review does not give dosing or treatment instructions.